HANGZHOU, China & NEWARK, Calif.–(BUSINESS WIRE)–Phase 2b/3 trial results show lingdolinurad significantly outperformed febuxostat in treating chronic gout and hyperuricemia

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.